Tizanidine Tablet
Product Images NDC 71610-864

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 71610-864). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0864 16)

Tizanidine 4 mg oral tablets packaging label showing a quantity of 6000 tablets. The label includes storage instructions, manufacturer details (Alkaloida Chemical Company Ltd., Hungary), and repackager information (Aphena Pharma Solutions - Tennessee, LLC). The label features barcodes and NDC 71610-864-16.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Tizanidine-1 (Tizanidine 1)

Chemical structure of Tizanidine hydrochloride, showing its ring systems with chlorine, sulfur, nitrogen atoms, and hydrochloride (HCl) component.*

FDA Label Image

Tizanidine-2 (Tizanidine 2)

A line graph depicting plasma tizanidine concentration (ng/mL) over time, measured in hours from dosing, for 4 mg tablets and capsules taken with and without food. The graph shows concentration peaks within 2 hours and gradual decline to near zero by 24 hours.*

FDA Label Image

Tizanidine-3 (Tizanidine 3)

A line graph illustrating improvement in Ashworth Score over time (hours post-dose) for 16 mg tizanidine, 8 mg tizanidine, and placebo groups. The vertical axis shows the improvement score, while the horizontal axis represents hours after dosing. The graph includes error bars for each data point.*

FDA Label Image

Tizanidine-4 (Tizanidine 4)

A line graph comparing improvement in Ashworth Score between tizanidine (mean dose 28.8 mg) and placebo across three time points: end of titration (study week 3), end of maintenance (study week 7), and endpoint (last observation carried forward). Tizanidine shows greater improvement (negative scores) with error bars, while placebo results cluster around minimal improvement with its own error bars.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.